TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06302010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball Intervention
Description: The stress ball has a soft plastic or silicone structure that can be held comfortably. Each ball is approximately 6 cm in diameter, in different colors, and is a soft toy that can be squeezed and manipulated with fingers to relieve stress and muscle tension and exercise the muscles (Apaydin Cirik et al., 2023). Squeezing a stress ball is a distraction and relaxation method. It is thought that squeezing a stress ball may be advantageous for reducing anxiety, considering its reliability, easy accessibility, effectiveness, low cost, sustainability, non-pharmacological and non-invasive properties.
Study: NCT04765657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclisiran sodium
Description: Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously injected on Day 1, 90, and 270.
Study: NCT06045754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab subcutaneous injection.
Study: NCT05300282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BEGEV
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BEGEV
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BEGEV
Description: In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I.
Study: NCT05735119

Intervention type: DEVICE
Intervention: Tapestry Biointegrative Implant
Description: Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
Study: NCT06465199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Description: DFMO for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Description: DFMO for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Description: DFMO for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Description: DFMO for IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Difluoromethylornithine (DFMO)
Description: DFMO for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT-1501 Dicaprate
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT-1501 Dicaprate
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT-1501 Dicaprate
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT-1501 Dicaprate
Description: Capsule
Study: NCT06643832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rubbing Distraction
Description: gently touching on proximal part of the IV injection site with the palm of the hand extending to the elbow. This will be started 5 seconds before propofol injection (not mixed with any drug) and continued until loss of consciousness. Also, a mobile video with duration of 10 seconds will be used for distraction and will be started 5 seconds before propofol injection so as to be ended at the time of first pain assessment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (drug)
Description: lidocaine will be used by mixing it with the propofol before intravenous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous propofol will be given without mixing with any drug (except for 2 ml saline to ensure blindness of the outcome assessor).
Study: NCT05868954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedDiet Program
Description: Subjects allocated to the MedDiet Program group will receive counseling based on the principles of the traditional MedDiet with a focus on a general change in diet instead of micronutrients or macronutrients. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional MedDiet meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive olive oil and nuts during their enrollment visit and during their routine 26-30 week prenatal visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACOG-based Dietary Program
Description: Following ACOG recommendation, subjects allocated to the ACOG-based Dietary Program group, will receive routine counseling on healthy eating. This will include advice on the consumption of grains, fruits, vegetables, protein, and dairy foods recommended during pregnancy. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional healthy meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive canola oil and healthy snacks during their enrollment visit and during their routine 26-30 week prenatal visit.
Study: NCT05653999

Intervention type: DEVICE
Intervention: Hearing Aids
Description: Hearing aids will be used by infants with a diagnosed sensorineural hearing loss.
Study: NCT06443125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural psychotherapy
Description: Draw ideas from traditional Chinese culture, learn from the practice of Morita therapy in Japan, and create local practice experience. At the same time, a variety of research methods such as cognitive assessment and brain imaging were used to establish the scientific, professional and objective evaluation indexes of the therapy.
Study: NCT04934865

Intervention type: DEVICE
Group type: OTHER
Intervention: Patients treated for their lung cancer.
Description: In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.~In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator.
Study: NCT04932434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Description: * Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring
Study: NCT06098755

Intervention type: BEHAVIORAL
Intervention: Transcendence Research: Holistic Education
Description: With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.

Intervention type: BEHAVIORAL
Intervention: Transcendence Research: Holistic Education
Description: With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.

Intervention type: BEHAVIORAL
Intervention: Transcendence Research: Holistic Education
Description: With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.

Intervention type: BEHAVIORAL
Intervention: Transcendence Research: Holistic Education
Description: With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.
Study: NCT06228079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy,Toripalimab Injection
Description: Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy,Gemcitabine based regimen
Description: Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
Study: NCT05700448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sugemalimab
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegaspargase
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion
Study: NCT05453773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Smoking
Description: Smoke waterpipe tobacco

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Smoking
Description: Smoke waterpipe tobacco

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Smoking
Description: Smoke waterpipe tobacco

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Smoking
Description: Smoke waterpipe tobacco
Study: NCT05193149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Training of respiratory muscles
Study: NCT06307964

Intervention type: PROCEDURE
Intervention: Biological sampling
Description: * A fragment of the diagnostic transjugular liver biopsy (D0)~* Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible~* Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible

Intervention type: PROCEDURE
Intervention: Biological sampling
Description: * A fragment of the diagnostic transjugular liver biopsy (D0)~* Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible~* Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible
Study: NCT05193149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Supervised aerobic exercise intervention

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise training
Description: Supervised aerobic exercise intervention
Study: NCT05508737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
Description: arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
Description: arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
Study: NCT04461301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal Prehabilitation
Description: A multimodal prehabilitation program (exercise, nutrition, anemia correction and smoking cessation).
Study: NCT06316856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD5 CAR T-cells
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Newly matched donor-derived CD5 CAR T-cells
Description: Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
Study: NCT05136417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-procedural intracardiac echocardiography (ICE) probe
Description: placing the WATCHMAN FLX device using the intra-procedural intracardiac echocardiography (ICE) probe.
Study: NCT05989308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email
Description: Email message sent to guardian with proxy information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text
Description: Text message sent to guardian with proxy information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Portal Message
Description: Patient portal message (MyChart) to guardian with proxy information.
Study: NCT05501379

Intervention type: OTHER
Intervention: No intervention - observational study only
Description: No intervention - observational study only
Study: NCT04758637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overdose Notification
Description: We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
Study: NCT04345250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction
Description: A 25% reduction in total caloric intake, as calculated through the app. Therefore, during the control period, participants will input what they consume into the Eat This Much app, then the app will calculate the 25% reduction in calories to present participants with how much to consume of the same foods. By doing this their diet will not be altered in terms of macronutrients or micronutrients, but solely on calories.
Study: NCT04298905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHW mHealth patient intervention for trigger escalation
Description: The CHW dashboard is a tablet-based, per-patient summary of the patient intervention. It is this dashboard that identifies a trigger to escalate the adherence intervention. This dashboard is created by receiving information from the patient's smartphone application as well as the National Health Laboratory Service (NHLS) data feed of laboratory results. The monitoring features included in this dashboard:~1. NHLS laboratory results: Dashboard receives and flags NHLS results for any positive smear or culture (new positive after prior negative results) or detectable viral load (with prior viral suppression)~   1. Triggered, escalating adherence coaching:~  2. Safety monitoring: reports all abnormal laboratory values to provider~2. Appointment keeping (RETAIN):~   a. Triggered, escalating adherence coaching~3. vDOT submissions:~   a. Triggered, escalating adherence coaching~4. Symptom reports:~   1. Triggered, escalating adherence coaching
Study: NCT05692674

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjuvant hypofractionated intensity-modulated proton radiotherapy
Description: CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
Study: NCT05071053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab (CYRAMZA®)
Description: Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine (SAR408701)
Description: Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion
Study: NCT06309953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miebo
Description: Miebo treatment
Study: NCT06544421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Assigned Interventions
Study: NCT05667246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeinated Coffee
Description: Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee.
Study: NCT05180487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
Study: NCT05384522

Intervention type: OTHER
Intervention: blood samples collection
Description: Blood samples will be drawn at baseline and at 6 and 12 months from baseline